Eiger BioPharmaceuticals, Inc. (EIGR) Cost of Revenue USD 2021 - 2023

Historical data

Taxonomy & unit
us-gaap: USD
Description
The aggregate cost of goods produced and sold and services rendered during the reporting period.
Summary
Eiger BioPharmaceuticals, Inc. annual/quarterly Cost of Revenue history and growth rate from 2021 to 2023.
  • Eiger BioPharmaceuticals, Inc. Cost of Revenue for the quarter ending September 30, 2023 was $115 K, a 90.7% decline year-over-year.
  • Eiger BioPharmaceuticals, Inc. annual Cost of Revenue for 2023 was $24 K, a 98.7% decline from 2022.
  • Eiger BioPharmaceuticals, Inc. annual Cost of Revenue for 2022 was $1.84 M, a 147% increase from 2021.
  • Eiger BioPharmaceuticals, Inc. annual Cost of Revenue for 2021 was $745 K.
Cost of Revenue, Trailing 12 Months (USD)
Cost of Revenue, Quarterly (USD)
Cost of Revenue, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2023 $115 K -$1.12 M -90.7% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q1 2023 $1.85 M $118 K +$8 K +7.27% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-11
Q4 2022 $1.84 M $345 K +$241 K +232% Oct 1, 2022 Dec 31, 2022 10-K 2024-04-08
Q3 2022 $1.6 M $1.23 M +$913 K +287% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $683 K $151 K -$119 K -44.1% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 $802 K $110 K +$57 K +108% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 $745 K $104 K Oct 1, 2021 Dec 31, 2021 10-K 2023-03-17
Q3 2021 $318 K Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $270 K Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $53 K Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
* An asterisk sign (*) next to the value indicates that the value is likely invalid.